A newly published article by Shoag et al. in the New England Journal of Medicine (NEJM) has suggested that the risks associated with “screening” for prostate cancer using the PSA test may not be as high as previously suggested. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: benefit, PSA, risk, screening, test | Leave a comment »
Slowly but surely we are learning more about the roles of family history and familial genetics (heredity) in determining risk for prostate cancer — and most especially risk for clinically significant forms of prostate cancer. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: family, germline, heredity, history, mutation, risk | 3 Comments »
So even if we don’t want to think or talk about it, most of us are well aware that about 40 percent of all Americans are now obese. In other words, they have a body mass index (BMI) of 30 kg/m2 or higher. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management | Tagged: BMI, body, index, mass, mortality, weight | Leave a comment »
The recommendations of the Philadelphia Prostate Cancer Consensus Conference 2019 (held in October last year) on implementation of germline testing for risk of prostate cancer have now been published in the Journal of Clinical Oncology. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: consensus, germline, risk, somatic, testing | 1 Comment »
Last month, we looked at Level 1 evidence (highest level, superseding all previous studies) that for unfavorable-risk patients, brachy boost therapy (BBT) — i.e., external beam therapy (EBRT) with a brachytherapy boost to the prostate — has better results when accompanied by 18 months of androgen deprivation therapy (ADT) (see this link). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: ADT, brachy boost, high, intermediate, radiation, risk, therapy | 2 Comments »
At the end of last year, Dendreon announced that the Phase III ProVent trial of sipuelucel-T (Provenge) in the treatment of men with relatively lower-risk forms of prostate cancer (as compared to active surveillance) had been fully enrolled ahead of schedule. … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: active, intermediate risk, low risk, Provenge, ProVent, sipuleucel-T, surveillance, trial | Leave a comment »
A new report from a relatively small, single-institution study has provided additional information about the utility of [18F]fluciclovine (Axumin) PET/CT scans in the detection of recurrent prostate cancer after definitive first-line treatment. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: Axumin, fluciclovine, PET/CT, recurrence, scan | 2 Comments »
For the past few years, some of us have been quietly concerned about the true value of MRI scans and the accuracy of PI-RADS scores in evaluation of a patient’s risk for the presence of clinically significant prostate cancer. This is a complex issue … but data from a large, recently completed study has now validated these concerns. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Risk | Tagged: MRI, PI-RADS, risk, scan, score | 18 Comments »
Jane Brody is an experienced journalist who writes regularly about issues related to health care in The New York Times. Your sitemaster regularly reads her columns because she does her homework with care and provides sound information for her readers. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, Brody, New York Times, screening, surveillance | 4 Comments »
As the Democratic Party discovered this week in Iowa, apps can have problems. However, there are also apps that prove to be very useful straight out of the gate — and they can be improved over time too. … READ MORE …
Filed under: Diagnosis | Tagged: app, FamGenix, health, predict, risk | Leave a comment »
There have long been suggestions that men already diagnosed with and receiving treatment for diabetes are at lower risk for a subsequent diagnosis of prostate cancer than non-diabetics. However, a very large, new, epidemiological analysis seems to suggest strongly that this may not be the case at all. … READ MORE …
Filed under: Diagnosis, Prevention, Risk | Tagged: ant-diabetic, diabetes, medication, Prevention, risk | 3 Comments »
A newly published paper by Blayer et al. in in the journal Cancer has stated that,
Worldwide, the incidence of prostate cancer has increased in all groups between ages 15 and 40 years and increased globally at a steady rate averaging 2% per year since 1990.
Filed under: Diagnosis, Risk | Tagged: age, Diagnosis, risk, youth | 2 Comments »
In posting the following commentary, we wish to be VERY clear that, at this time, there is no definitive evidence that there is a causal relationship between male infertility and risk for prostate cancer, but this does appear to be a POSSIBILITY. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: assistaed, Diagnosis, fertility, male, reproduction, risk | Leave a comment »
